Peter Galettis
Overview
Explore the profile of Peter Galettis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
748
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Glewis S, Michael M, Gurney H, Olver I, Zdenkowski N, Ackland S, et al.
Br J Clin Pharmacol
. 2025 Feb;
PMID: 39988750
Aim: PREDICT-5FU aimed to document 5-fluorouracil (5FU) exposure in a cancer population and to evaluate the feasibility of 5FU and capecitabine therapeutic drug monitoring (TDM) in patients receiving standard doses...
2.
Razmovski-Naumovski V, Martin J, Chye R, Phillips J, Lintzeris N, Solowij N, et al.
J Pain Symptom Manage
. 2025 Feb;
PMID: 39988015
Context: Evaluating medicinal cannabis in clinical trials is important for informing its efficacy and safety in clinical care. Alongside the inherent practical challenges of conducting clinical trials in people receiving...
3.
Radovanovic M, Schneider J, Martin J, Norris R, Galettis P
J Mass Spectrom Adv Clin Lab
. 2024 Aug;
33:31-37.
PMID: 39206041
When quantifying therapeutic drugs using LC-MS/MS instrumentation in clinical laboratories, batch-mode analysis with a calibration curve consisting of 6-10 concentrations for each analyte is the most widely used approach. However,...
4.
Flynn A, Galettis P, Gurney H, Michael M, Desar I, Westerdijk K, et al.
Intern Med J
. 2024 May;
54(9):1458-1464.
PMID: 38767393
Background: In the development of anticancer agents for solid tumours, body surface area continues to be used to personalise dosing despite minimal evidence for its use over other dosing strategies....
5.
Martin J, Galettis P, Flynn A, Schneider J
Pharmacol Res Perspect
. 2024 Mar;
12(2):e1182.
PMID: 38429945
Cancer medicines often have narrow therapeutic windows; toxicity can be severe and sometimes fatal, but inadequate dose intensity reduces efficacy and survival. Determining the optimal dose for each patient is...
6.
Erku D, Martin J, Michael M, Galettis P, Scuffham P
Br J Clin Pharmacol
. 2024 Feb;
PMID: 38346317
Aims: Using pharmacokinetics (PK)-guided 5-fluorouracil (5-FU) for metastatic colorectal cancer (mCRC) improves overall survival (OS) and decreases toxicity, yet its value for money in the Australian setting is unknown. Our...
7.
Radovanovic M, Galettis P, Flynn A, Martin J, Schneider J
Pharmaceuticals (Basel)
. 2024 Jan;
17(1).
PMID: 38256896
Paclitaxel is an anticancer agent efficacious in various tumors. There is large interindividual variability in drug plasma concentrations resulting in a wide variability in observed toxicity in patients. Studies have...
8.
Shafiei M, Galettis P, Beale P, Martin J, McLachlan A, Blinman P
J Pharm Pharmacol
. 2023 Dec;
76(2):86-92.
PMID: 38134956
Objectives: Therapeutic drug monitoring allows personalized dosing of chemotherapy, but is not well established for capecitabine. The aim of this study was to compare the concentrations of capecitabine and its...
9.
Tong Z, Esser L, Galettis P, Rudd D, Easton C, Nilghaz A, et al.
Biosensors (Basel)
. 2023 Aug;
13(8).
PMID: 37622865
Microfluidic technology is applied across various research areas including organ-on-chip (OOC) systems. The main material used for microfluidics is polydimethylsiloxane (PDMS), a silicone elastomer material that is biocompatible, transparent, and...
10.
Lorenzetti V, McTavish E, Broyd S, van Hell H, Thomson D, Ganella E, et al.
Cannabis Cannabinoid Res
. 2023 Aug;
9(4):e1108-e1121.
PMID: 37603080
Cannabis use is associated with brain functional changes in regions implicated in prominent neuroscientific theories of addiction. Emerging evidence suggests that cannabidiol (CBD) is neuroprotective and may reverse structural brain...